Plain-English translation of NCT04480853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a 12-month safety study of , a medication for people with relapsing-remitting multiple sclerosis in Taiwan who are starting treatment for the first time. Participants will take the medication daily while doctors monitor them closely to ensure it is working well and is safe. The study will involve visits to the clinic where researchers will check on your health and any side effects.
This study exists to make sure that this medication works safely in people with multiple sclerosis in Taiwan and to catch any side effects early so doctors can help quickly if needed.
You likely qualify if…
You likely don't qualify if…
You will take one 0.5 mg capsule of the medication by mouth each day for 12 months. You will visit the clinic multiple times for check-ups where doctors will ask about side effects, do blood tests, and run other safety tests. Beyond these study visits, your regular multiple sclerosis care will continue as your doctor normally manages it. If you need to stop the medication for any reason, your participation in the study may end.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Taiwan